Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

James J Nawarskas

Showing results (1-10 of 40) with videos related to

Pageof 4
Sort By:
Cardiology in Review|February 12, 2005
HMG-CoA reductase inhibitors and coenzyme Q10James J Nawarskas
Cardiology in Review|August 19, 2004
Clopidogrel--statin interactionJames J Nawarskas
Cardiology in Review|May 30, 2020
Nitrosamine Impurities in Angiotensin Receptor BlockersEmily A Shephard, James J Nawarskas
American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists|October 22, 2005
Paclitaxel-eluting stents in coronary artery diseaseJames J Nawarskas, Larry A Osborn
Cardiology in Review|October 27, 2018
Andexanet Alfa for Reversing Factor Xa InhibitionAlexandra M Sible, James J Nawarskas
Expert Review of Pharmacoeconomics & Outcomes Research|May 1, 2009
Quality-adjusted life-years as decisionmaker tools to address limitations inherent in number-needed-to-treat/harm valuesDennis W Raisch, James J Nawarskas
Cardiology in Review|October 8, 2013
Treatment options for patients with poor clopidogrel responseDaniela I Roberts, James J Nawarskas
Cardiology in Review|December 8, 2017
Switching From Ticagrelor or Prasugrel to ClopidogrelJames J Nawarskas, Tiffany N Montoya
Cardiology in Review|June 14, 2005
Ranolazine. A metabolic modulator for the treatment of chronic stable anginaJoe R Anderson, James J Nawarskas
Heart Disease (Hagerstown, Md.)|July 31, 2002
Levosimendan: a unique approach to the treatment of heart failureJames J Nawarskas, Joe R Anderson
Pageof 4

Showing results (1-10 of 40) with videos related to

Sort By:
Pageof 4
Cardiology in Review|February 12, 2005
HMG-CoA reductase inhibitors and coenzyme Q10James J Nawarskas
Cardiology in Review|August 19, 2004
Clopidogrel--statin interactionJames J Nawarskas
Cardiology in Review|May 30, 2020
Nitrosamine Impurities in Angiotensin Receptor BlockersEmily A Shephard, James J Nawarskas
American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists|October 22, 2005
Paclitaxel-eluting stents in coronary artery diseaseJames J Nawarskas, Larry A Osborn
Cardiology in Review|October 27, 2018
Andexanet Alfa for Reversing Factor Xa InhibitionAlexandra M Sible, James J Nawarskas
Expert Review of Pharmacoeconomics & Outcomes Research|May 1, 2009
Quality-adjusted life-years as decisionmaker tools to address limitations inherent in number-needed-to-treat/harm valuesDennis W Raisch, James J Nawarskas
Cardiology in Review|October 8, 2013
Treatment options for patients with poor clopidogrel responseDaniela I Roberts, James J Nawarskas
Cardiology in Review|December 8, 2017
Switching From Ticagrelor or Prasugrel to ClopidogrelJames J Nawarskas, Tiffany N Montoya
Cardiology in Review|June 14, 2005
Ranolazine. A metabolic modulator for the treatment of chronic stable anginaJoe R Anderson, James J Nawarskas
Heart Disease (Hagerstown, Md.)|July 31, 2002
Levosimendan: a unique approach to the treatment of heart failureJames J Nawarskas, Joe R Anderson
Pageof 4